The nerve to expect more. The nerve to redefine patients expectations.

The VNS Therapy™ System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications.

VNS Therapy may be associated with lower SUDEP rates.⁴

In a retrospective claims analysis, age-adjusted SUDEP rates decreased over time from years 1 to 2 (2.47/1000 person-years) to years 3 to 10 (1.68/1000 person-years).* A study on 277,661 person-years of up to 10 years of follow-up and 3689 deaths, including 632 cases of SUDEP, showed that long-term VNS Therapy is associated with lower SUDEP rates. The data suggest that SUDEP risk decreases during long-term follow-up of patients with refractory epilepsy receiving VNS Therapy.

*Limitations: This finding might reflect several factors, including ASM use, lack of a control group/seizure baseline, the natural long-term dynamic of SUDEP rate, attrition, and the impact of VNS Therapy. The role of each of these factors cannot be confirmed due to the limitations of study.

Epilepsy (US) – The VNS Therapy System is indicated for use as an adjunctive therapy in reducing thefrequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications.

VNS Therapy^™ Safety Profile

The most common side effects of VNS Therapy include:

Hoarseness
Shortness of breath
Sore throat
Coughing

These side effects generally only occur during stimulation and usually decrease over time.

Infection is the most common side effect of the procedure.

You can find more safety information here.

References: 1. Data on file. Survey report. LivaNova USA, Inc. Houston, TX. October 2021. 2. Orosz I, McCormick D, Zamponi N, et al. Epilepsia. 2014;55(10):1576-1584. 3. Englot DJ, Hassnain KH, Rolston JD, Harward SC, Sinha SR, Haglund MM. Epilepsy Behav. 2017;66:4-9. 4. Ryvlin P, So EL, Gordon CM, et al. Epilepsia. 2018;59(3):562-572. 5. Ben-Menachem E. J Clin Neurophysiol. 2001;18(5):415 418. 6. Epilepsy Patient’s Manual for Vagus Nerve Stimulation, LivaNova, Inc., Houston, TX. 7. Morris GL, Mueller WM. Neurology. 1999;53(7):1731-1735.

Choose a country

For ALL other countries, please click here.

The nerve to expect more. The nerve to redefine patients expectations.

In a survey of 200 VNS Therapy™ patients and caregivers¹:

VNS Therapy™ reduces the frequency, duration, and severity of seizures and improves postictal recovery

One-third of patients were considered "much improved" or "very much improved" following 12 months of adjunctive VNS Therapy^TM (n=78), with sustained and improved scores continuing up to 24 months.²

3 out of 4 patients experience improvements in overall quality-of-life³

VNS Therapy may be associated with lower SUDEP rates.⁴

Empower your patients and discuss VNS Therapy™ earlier

VNS Therapy^TM Safety Profile

VNS Therapy is proven to be a safe adjunctive treatment and is well-tolerated by most patients without contributing to ASM toxicity.^5,6

The most common side effects of VNS Therapy occur during stimulation and generally become less noticeable over time for most patients.^5,7 Infection is the most common complication of the procedure.⁶

VNS Therapy™ has no neurotoxic effects or drug interactions^5,6

VNS Therapy^™ Safety Profile

Access resources to support your practice and patients

Hear patient stories

Choose a country

For ALL other countries, please click here.

The nerve to expect more. The nerve to redefine patients expectations.

In a survey of 200 VNS Therapy™ patients and caregivers1:

VNS Therapy™ reduces the frequency, duration, and severity of seizures and improves postictal recovery

One-third of patients were considered "much improved" or "very much improved" following 12 months of adjunctive VNS TherapyTM (n=78), with sustained and improved scores continuing up to 24 months.2

3 out of 4 patients experience improvements in overall quality-of-life3

VNS Therapy may be associated with lower SUDEP rates.4

Empower your patients and discuss VNS Therapy™ earlier

VNS TherapyTM Safety Profile

VNS Therapy is proven to be a safe adjunctive treatment and is well-tolerated by most patients without contributing to ASM toxicity. 5,6

The most common side effects of VNS Therapy occur during stimulation and generally become less noticeable over time for most patients.5,7 Infection is the most common complication of the procedure.6

VNS Therapy™ has no neurotoxic effects or drug interactions5,6

VNS Therapy™ Safety Profile

Access resources to support your practice and patients

Hear patient stories

In a survey of 200 VNS Therapy™ patients and caregivers¹:

One-third of patients were considered "much improved" or "very much improved" following 12 months of adjunctive VNS Therapy^TM (n=78), with sustained and improved scores continuing up to 24 months.²

3 out of 4 patients experience improvements in overall quality-of-life³

VNS Therapy may be associated with lower SUDEP rates.⁴

VNS Therapy^TM Safety Profile

VNS Therapy is proven to be a safe adjunctive treatment and is well-tolerated by most patients without contributing to ASM toxicity.^5,6

The most common side effects of VNS Therapy occur during stimulation and generally become less noticeable over time for most patients.^5,7 Infection is the most common complication of the procedure.⁶

VNS Therapy™ has no neurotoxic effects or drug interactions^5,6

VNS Therapy^™ Safety Profile